Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1931-1939

  Sanchez, E ^a   Chacon, I ^a   Plaza, M M ^a   Munoz E ^a   Cruz, M A ^a   Martinez, B ^a   Lopez, L ^a   Martinez Montero, J C ^a   Orradre, J L ^a   Saez, A I ^a   Garcia, J F ^a   Piris, M A ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0031834553     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1931     Document Type: Article

References (44)

1. Harris NL, Jaffe ES, Stein H, et al.: A revised European-American classification of lymphoid neoplasm: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392,1994
2. Kramer MHH, Hermans J, Parker J, et al.: Clinical significance of bc!2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study. J Clin Oncol 14:2131-2138,1996
3. Hermine O, Haioun C, Lepage E, et al. for the Groupe d'Etude des Lymphomes de l'Adulte (GELA): Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87:265-272,1996
4. Hill ME, MacLennan KA, Cunningham DC, et al.: Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large non-Hodgkin's lymphoma: A British National Lymphoma Investigation study. Blood 88:1046-1051,1996
5. Piris MA, Pezella F, Martînez-Montero JC, et al.: p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time. BrJ Cancer 69:337-341,1994
6. Gascoyne RD, Adomat SA, Krajewski S, et al.: Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244-251, 1997
7. Louie DC, Offit K, Jaslow R, et al.: p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14) (q13;q32). Blood 86:2892-2899, 1995
8. WAFI/CIPI and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: A p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations. J Pathol 181:51-61,1997
9. Maestro R, Gloghini A, Doglioni C, et al.: MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. Blood 85:3239-3246,1995
10. Maestro R, Gloghini A, Doglioni C, et al.: Human non-Hodgkin's lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21. Blood 89:2523-2528, 1997
11. Cance WG, Brennan MF, Dudas ME, et al.: Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 323:1457-1462,1990
12. Gerdes J, Lemke H, Baisch H, et al.: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715,1984
13. Grogan TM, Lippman SM, Spier CM, et al.: Independent prognostic significance of a nuclear proliferation antigen in diffuse large-cell lymphomas as determined by the monoclonal antibody Ki-67. BIood71:1157-1160,1988
14. Miller TP, Grogan TM, Dahlberg S, étal: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 83:1460-1466,1994
15. Velders GA, Kluin-Nelemans JC, De Boer CJ, et al.: Mantle-cell lymphoma: A population-based clinical study. J Clin Oncol 14:1269-1274,1996
16. Martin AR, Weisenburger DD, Chan WC, et al.: Prognostic value of cellular proliferation and histologie grade in follicular lymphoma. Blood 85:3671-3678, 1995
17. Slymen DJ, Miller TP, Lippman SM, et al.: Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin Oncol 8:986-993,1990
18. Yamanaka N, Harabuchi Y, Kataura A: The prognostic value of Ki-67 antigen in non-Hodgkin's lymphoma of Waldeyer ring and the nasal cavity. Cancer 70:2342-2349,1992
19. Tominaga K, Yamaguchi Y, Nozawa Y, et al.: Proliferation in non-Hodgkin's lymphomas as determined by immunohistochemical double staining for Ki-67. Hematol Oncol 10:163-169,1992
20. The International Non-Hodgkin's Lymphoma Prognostic Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994,1993
21. Villuendas R, Piris MA, Orradre JL, et al.: p53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 166:235-241, 1992
22. Nakamura S, Akazawa K, Kinukawa N, et al.: Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma. Hum Pathol 27:225-233,1996
23. Morente MM, Piris MA, Abraira V, et al.: Adverse clinical outcome in Hodgkin's disease is associated with loss of Rb expression, high Ki67 proliferative index and absence of EBV-LMP1 expression. Blood 90:2429-2436, 1997
24. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958
25. Mantel N: Evaluation of survival and two new rank order statistics arising in its consideration. Cancer Chemotlier Rep 50:163-170, 1966
26. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220,1972
27. Abraira V, Ferez de Vargas A (eds): Métodos Multivariantes en Bioestadi'stica. Madrid, Spain, Centra de Estudios Ramón Areces, 1966
28. Hemdndez L, Fest T, Cazorla M, et al.: p-53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87:3351-3359, 1996
29. Sander CA, Yano T, Clark HM, et al.: p53 mutation is associated with progression in follicular lymphomas. Blood 82:1994-2004, 1993
30. Du M, Peng H, Singh N, et al.: The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 86:4587-4593,1995
31. Ichikawa A, Kinoshita T, Watanabe T, et al.: Mutation of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529-534,1997
32. Villuendas R, Pins MA, Algara P, et al.: The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 82:3151-3156,1993
33. + anaplastic large-cell lymphoma: High frequency of c-myc proto-oncogene activation. Blood 83:3581-3590, 1994
34. Martfnez JC, Mateo M, Sânchez-Beato M, et al.: MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. J Pathol 177:27-34, 1995
35. Martin K, Trouche D, Hagemeier C, et al.: Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375:691-694,1995
36. Xiao Z-X, Chen J, Levine AJ, et al.: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694-698,1995
37. Watanabe T, Hotta T, Ichikawa A, et al.: The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84:3158-3165, 1994
38. Sandig V, Brand K, Herwig S, et al.: Adenovirally transferred pjgiNK4/cDKN2 ancj p53 genes cooperate to induce apoptotic tumor cell death. Nature Med 3:313-319,1997
39. Chott A, Augustin I, Wrba F, et al.: Peripheral T-cell lymphomas: A clinicopathologic study of 75 cases. Hum Pathol 21:1117-1125, 1990
40. Gerdes J, Stein H, Pileri S, et al.: Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet 2:448-449, 1987
41. Hall PA, Richards MA, Gregory WM, et al.: The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 154:223-235,1988
42. Wilson WH, Teruya-Feldestein J, Fest T, et al.: Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89:601-609,1997
43. Tang SC, Visser L, Hepperle B, et al.: Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: An analysis of 83 cases. J Clin Oncol 12:149-154, 1994
44. Walton MI, Whysong D, O'Connor PM, et al.: Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin-induced apoptosis. Cancer Res 53:1853-1861,1993